Colloids are commonly used for cardiovascular resuscitation. In South Australia until recently Haemaccel® (Aventis Pharma Pty. Ltd.) was used exclusively in hospitals and in the ambulance service.
However, in the middle of the year 2000, the South Australian Ambulance Service decided to carry Gelofusin® (B Braun Australia Pty. Ltd.) as the blood volume expander on its ambulances instead of Haemaccel. We received an enquiry from a patient who became aware of this change as to the implications for him as he was known to have suffered an anaphylactic reaction to Haemaccel.
As both Haemaccel and Gelofusin are modified gelatines derived from Bovine-SpongiformEncephalitis-free bovine herds in the U.S.A., it is possible that they could exhibit cross-reactivity. Haemaccel is a urea-linked modification with a molecular weight about 35,000 while Gelofusin is succinate-linked with a mean molecular weight of 30,000. The 2001 MIMS Australia product statements for both colloids contain a warning that each has been associated with rare but severe reactions similar to anaphylaxis 1 .
Examination of the accompanying literature for both Haemaccel and Gelofusin and reviewing the product information in MIMS did not provide any guide as to the risk of cross-reactivity. If any of these patients required volume loading during an emergency, it might be possible that the ambulance officer may not appreciate the similarity between Haemaccel declared on their Medic Alert bracelet and the Gelofusin available in the ambulance. Indeed, no evidence was found by literature search or from either manufacturer to support or refute the possibility of cross-reactivity.
In view of these uncertainties, the database of allergic patients held by the first author at the Royal Adelaide Hospital was examined. Four patients with known reaction to Haemaccel were found. All these patients had been offered a Medic Alert bracelet with the inscription "Allergic to Haemaccel". These patients were contacted by letter and the changes in S.A. Ambulance policy explained. They were offered further skin testing to ascertain if they were also allergic to Gelofusin. Two patients accepted this offer.
CASE HISTORIES Patient 1
Original Reaction: This man was scheduled for an endoscopic transurethral resection of his prostate. He was given intravenous midazolam and metoclopramide and spinal anaesthesia was instituted using lignocaine 1% for skin anaesthesia and 3 ml bupivacaine 0.5% for the subarachnoid block. Shortly after the block was inserted his systolic blood pressure fell from 130 to 110 mmHg, he complained of nausea and he was given ephedrine IV and a rapid infusion of normal saline. When the saline was completed, an infusion of Haemaccel was begun. He began to complain of burning in his chest "like hiatus hernia pain" and was given oral sodium citrate 30 ml. He became more restless. Shortly after this, his systolic blood pressure fell to 70 mmHg and he was given ephedrine 6 mg IV and metaraminol 0.1 mg IV. His blood pressure continued to fall to a systolic of 50 mmHg despite more ephedrine and metaraminol. At this point he was given IV adrenaline and his blood pressure returned to 100 mmHg systolic. It was then noticed that florid red wheals had developed on his arms, chest and thighs. In addition to the adrenaline (860 µg total), he received IV Albumex ® (4% albumen, CSL) two units (1 litre). He was observed in the Intensive Care Unit for 24 hours and then transferred to the ward. A mast cell tryptase taken about 30 minutes after the onset was measured at 21.3 IU (N<13.5). Intradermal skin testing nine weeks after the reaction showed a 15 mm wheal and 30 mm flare to Haemaccel diluted to 1/100. There was no reaction to intradermal injection of to 1/100 dilution of lignocaine, midazolam, metoclopramide or bupivacaine.
Further Testing: Three years later, retesting with 1/00 dilution of Haemaccel and Gelofusin showed 15/25 mm and 12/20 mm (wheal/flare) respectively (Figure 1 ).
Patient 2
Original Reaction: This man was scheduled for a third revision of his total hip replacement. His previous revision was two years before. The anaesthetic technique was a combined epidural and general anaesthesia. During the procedure he received 2.5 litres of Haemaccel and 1.5 litres of autologous blood. He was suffering mild hypertension for which he received indapamide and diabetes controlled by diet. He was also on prednisolone 10 mg alternate days for arthritis and beclomethasone and salbutamol inhalation. His only known allergy was to "Coca Cola" causing facial swelling. After a lumbar epidural was inserted, he was given general anaesthesia consisting of fentanyl, propofol and atracurium with nitrous oxide and isoflurane. After the induction of anaesthesia, a radial artery line was inserted and 3 ml of 2% lignocaine was given thorough the epidural catheter. At this point his blood pressure was 80/55 mmHg. He was given ephedrine and metaraminol and a rapid infusion of saline was commenced followed by Haemaccel. Shortly after this he became severely hypotensive with an unrecordable blood pressure (<30 mmHg systolic) which responded poorly to metaraminol but did respond to high-dose adrenaline and fluid loading with more Haemaccel. Anaphylaxis was suspected and the operation cancelled. A mast cell tryptase taken at about one hour was found later to be 42.7 IU (N<13.5). Five weeks later he was tested with intradermal injections of the drugs given at a dilution of 1/100. The only positive result was with Haemaccel, 15/30 mm (wheal/flare) at 30 minutes. Fentanyl, propofol, atracurium and lignocaine were tested but gave no intradermal reaction.
Further Testing: Three years later, retesting with 1/100 dilution of Haemaccel and Gelofusin showed 10/15 mm and 13/25 mm (wheal/flare) respectively (Figure 2) .
Both of these patients have been given a new Medic Alert stating "Allergic to Haemaccel and to Gelofusin".
DISCUSSION
From these two patients with proven anaphylaxis to Haemaccel, it would appear that Gelofusin has a strong cross reactivity. Patients who are allergic to Haemaccel must be considered allergic to Gelofusin until proven otherwise. Whether patients allergic to Gelofusin will cross-react strongly to Haemaccel remains to be determined, but should be considered so as the conservative option until demonstrated otherwise. Thus where patients are identified as allergic to either of these colloids it should be assumed that the alternative colloid is also capable of causing an allergic reaction. Hospital staff and ambulance officers should be advised that any patient who is known to be allergic to either of these agents should not receive the other. If a patient requires colloid then the best option is Albumex as this should have no cross-reactivity.
It is of interest that the second patient recovered with adrenaline and more Haemaccel even though he was subsequently found to be allergic to the Haemaccel. It would appear that the initial dose of Haemaccel probably absorbed all of the specific antibody and there was no further reaction during resuscitation as loss of the antibody had rendered the patient temporally immunologically incompetent.
